Highlights
The Stroke Secondary Prevention With Catheter Ablation and Edoxaban for Patients With Nonvalvular Atrial Fibrillation (STABLED) trial investigated whether catheter ablation combined with oral anticoagulation (OAC) is superior to OAC alone for secondary stroke prevention.
The primary composite end point—including recurrent ischemic stroke, systemic embolism, all-cause mortality, and hospitalization for heart failure—showed no statistically significant difference between the two groups (HR, 1.11; 95% CI, 0.62-2.01).
